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BACKGROUND 
1. Basic features of Smad proteins 
1.1.1 Smad family members 
SMADs (small mothers against decapentaplegic) are intracellular 
proteins that transduce extracellular signals from transforming growth 
factor beta (TGF-β) ligands to the nucleus where they activate 
downstream TGF-ß gene transcription (Massaguè, 1998; Wrana et al, 
2000). The name Smads was coined in reference to its sequence 
similarity to the Drosophila Medea protein, mothers against 
decapentaplegic “Mad” and to the Caenorhabditis elegans protein 
“Sma”. Actually eight Smad proteins are encoded in the human and 
mouse genome, four in Drosophila and three in C. elegans (Massaguè, 
1998) (Figure 1). Only five of the mammalian Smads (R-Smads, namely 
Smad1, Smad2, Smad3, Smad5 and Smad8) act as substrates for the 
TGF-β receptors family; indeed Smad1, 5, and 8 act mainly as substrates 
for the Bone Morphogenetic Protein (BMP) and anti-Muellerian 
receptors, while Smad2 and 3 are substrates for the TGF-β, activin and 
nodal receptors. Co-Smad-Smad4 serves as a common partner for all R-
Smads while Smad6 and 7 are inhibitory proteins. Functional studies, 
together with the X-ray crystal structure analyses, showed that these ~500 
amino acids proteins consist of two conserved globular domains (MH1 and 
MH2 domains) coupled by a flexible linker region rich of binding sites for 
Smurf (Smad ubiquitination-related factors) ubiquitin ligase, of 
phosphorylation sites for several classes of protein kinases and, in Smad4, a 
nuclear export signal (NES) involves on nucleus-cytoplasmatic 
translocation (Massaguè et al, 2005) (Figure 2). The N-terminal Mad-
Homology 1 (MH1) domain is conserved in all R-Smads and in Co-Smad 
but not in inhibitory Smads; it functions as DNA-binding site containing a 
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β-hairpin structure and is stabilized by a tightly bound zinc atom (Shi et al, 
1997; Dennler et al, 1998), furthermore it can interact with other proteins 
and carries nuclear localization signals (NLSs). The C-terminal MH2 
domain is conserved in all Smads and is involved on type I receptor 
binding, on Smad homo-and hetero-oligomerization and on R-Smad 
activation/phosphorylation (Dijke et al, 2006). Nearby, in R-Smads, a basic 
pocket interacts with the phosphorylated region of the activate receptor type 
I, or with the phosphorylated tail of R-Smad, in case of Smad4; in the other 
site, a set of contiguous hydrophobic patches, constituting the 
“Hydrophobic corridor”, are involved in interaction with nucleoporins and 
cytoplasmatic retention proteins (Ross et al, 2008). 
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Figure 1: Three subclasses of Smads. The receptor-regulated Smads 
include two groups of closely related forms; the SSXS receptor 
phosphorylation sequence (P) is located in the C-terminus or receptor 
regulated Smads. The Co-Smads include Drosophila Medea and C. 
elegants Sma-4, which are more similar to Smad4 than to any other family 
member. Antagonistic Smads lack most of the conserved MH1 domain and 
their MH2 domain is quite divergent from the MH2 domain if the other 
family members (Massaguè et al, 2005). 
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Figure 2: Molecular structure of Smads and interaction sites in TGF-β type 
I receptor cytoplasmatic domain (Massaguè et al, 2005). 
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1.1.2 Receptor internalisation 
Binding of TGF-β to the type I and type II receptors, induces formation of 
heterotetrameric complexes in the presence of the dimeric ligand (Wrana et 
al, 2008). The serine/threonine kinase receptor family in the human genome 
comprises 12 members, 7 type I and 5 type II receptors, all involved in 
TGF-β signaling; both types of receptors consist of about 500 amino acids, 
organized sequentially into a N-terminal extracellular ligand binding 
domain, a transmembrane region, and a C-terminal serine/threonine kinase 
domain. In contrast with BMPs, TGF-β and activin display an high affinity 
for the type II receptor (TβRII) and do not interact with the isolated type I 
receptor (TβRI) (Massaguè et al, 1998). Initially TGF-β binds tightly to the 
ectodomain of the type II receptor, this binding allows the subsequent 
dimerization with the type I receptor, forming a large ligand-receptor 
complex in which are involved a dimeric ligand and four receptor 
molecules. Lin (Lin et al, 2006) suggested that once type II receptors 
phosphorylate type I receptors, they could interact at the cell surface with 
the cytoplasmatic form of promyelocytic leukemia protein (cPML) that acts 
as a bridging factor between a Smad Anchor for Receptor Activation 
(SARA) and Smad2/3. cPML promotes the transfer of the complex formed 
into early endosomes, where cPML could dissociate from the complex, 
allowing Smad2/3 to interact with SARA and to be phosphorylated. SARA 
is an anchor protein which acts presenting R-Smads to the activated type I 
receptor and thereby regulating TGF-β transduction signal. It is a 
multidomain protein that contains an 80 amino acids Smad-Binding 
Domain (SBD) and a FYVE phospholipid-binding domain that avidly binds 
to phosphatidyl inositol 3-phosphate on endosomal membranes and targets 
SARA preferentially to early endosomes (Di Guglielmo et al, 2003). As 
revealed by the X-ray crystal structure of the Smad2–SBD complex, the 
SBD of SARA makes contact with the three consecutive hydrophobic 
patches of the hydrophobic corridor (Wu et al, 2000), blocking 
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translocation of Smad2/3 into the nucleus and the formation of 
transcriptional complexes; the activated TGF-β receptor complex therefore 
undergoes endocytosis via two distinct routes: by internalization via coated 
vesicles to early endosomes and via caveolae to caveolin-positive vesicles 
for degradation (Di Guglielmo et al, 2003). However other adaptor proteins 
were found to cooperate with SARA on Smad signaling, such as FYVE-
containing protein, HGS (Mirura et al, 2000) Disabled-2 (Hocevar et al, 
2001), Axin (Furuhashi et al, 2001), and the ELF β-spectrin (Tang et al, 
2003). 
 
1.1.3 Smad phosphorylation and nuclear translocation 
In the basal state, Smads form homoligomers and remain in an inactive 
conformation through an hydrophobic interaction between the MH1 and 
MH2 domains. In solution, the unphosphorylated Smad2 MH2 domain is a 
monomer but, once phosphorylated, both R-Smads and Smad4 form 
homotrimic complexes (Lagna et al, 1996; Shi et al, 1997). As revealed by 
X-ray crystallographic studies, the binding of R-Smad to Smad4 forms 
oligomers, heterodimers (R-Smad–Smad4) or heterotrimers (two R-Smads 
molecules plus one Smad4 molecule) which are stabilized by interactions 
within an extensive protein–protein interface between adjacent MH2 
domains (Wu et al, 2001). Phosphorylation can occur in two different sites: 
in the linker region sites by several kinases, including MAPKs and CDK 
(Brown et al, 1999; Shi et al, 2004) and mainly on the C-terminal 
conserved Ser-Val-Ser (Ser-Met-Ser in Smad2) motif of Smad3 by the 
activated receptor (Massaguè et al, 2005; Ross et al, 2008). Actually the 
cytoplasmatic region of the type I receptor contains a canonical protein 
kinase domain preceded by a regulatory region or GS domain to which the 
inhibitor FKBP12 binds to enforce the inactive basal state. Phosphorylation 
of the GS domain by the type II receptor creates a repeated pS-X-pS motif 
that serves as a docking site for both R-Smads (Massaguè et al, 2005); as a 
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result, R-Smads decrease their affinity for SARA and the activated 
oligomer complex is translocated into the nucleus where can bind directly 
to DNA promoters or indirectly binding to transcription factor or co-
factors. (Xu et al, 2000; 2002). Recently two studies showed that In the 
basal state, R-Smads are predominantly localized in the cytoplasm, I-Smads 
tend to be nuclear, while Smad4 is distributed equally in both, cytoplasm 
and nucleus; however Smads do not reside statically in the cytoplasm in 
absence of ligands or in the nucleus upon TGF-β stimulation: there is a 
spontaneous bi-directional shuttling of the R-Smads/Smad4 complex across 
the nuclear envelope without TGF-β stimulation (Xu et al, 2002) even if the 
nuclear import of the oligomer complex is offset by export forces, so they 
cannot reach an high concentration in the nucleus (Nicolas et al, 2004). 
However TGF-β-independent signals can involve target sites rich of 
multiple serine and threonine, as on the linker region as on the N-terminal 
domain. Indeed the linker regions of R-Smads are subject to 
phosphorylation by Cam Kinase II (Ca++- and Calmodulin-dependent 
kinase II) (Wicks et al, 2000), while the N-terminal and the linker region of 
Smad3 can be phosphorylated by cyclin-dependent kinases (CDKs) 
(Matsuura et al, 2004) or by G protein-coupled receptor kinase 2 (GRK-2)  
which phosphorylates Ser197 in Smad2 (Ho et al, 2005).  
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Figure 3: Molecular mechanism of Smads pathway. 1-2) Upon TGF-β 
binding, anchor protein SARA captures R-Smads (Smad2/3) for 
presentation to the activated type I receptor. 3-4 ) Activated R-Smads 
dissociate from the receptor/SARA complex and form an oligomeric 
complex with Co-Smad-Smad4. 5-6-7) The complex R-Smad/Co-Smad 
translocates into the nucleus where can bind to transcription factors or 
directly interact with DNA in Smad Binding Elements (SBE). 8) Gene 
target transcription is activated. 9) I-Smads inhibit signals competing with 
R-Smads for interacting with type I receptor and preventing 
phosphorylation (Magno et al, 2008). 
 
 
 
 
 
SARA 
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1.1.4 Post-translational regulation of Smads 
Smad activation and transcriptional functions can be regulated in both 
cytoplasm and nucleus. Several types of mechanisms were evolved to limit 
their activity (Figure 4): one type includes transcriptional co-repressors, 
such as the homeodomain protein TGIF. Binding of TGIF prevents the 
interaction of Smads with nuclear co-activators and interferes with 
activation of TGF-β-target genes expression. The inhibitory Smads, Smad6 
and 7, interfere with Smad-receptors or Smad-Smad interactions; Smad7 
inhibits TGF-β/activin and BMP signaling, while Smad6 inhibits more 
selectively the BMP pathway showing high selectivity for specific amino 
acid residues of the BMP type I receptors, ALK1, ALK2, ALK3 and ALK6 
(Goto et al, 2007). Smad6 competes with Smad4 for interaction with the 
receptor-activated Smad1, such that inactive Smad1-Smad6 complexes are 
formed (Hata et al, 1998). In contrast, Smad7 acts as a competitive inhibitor 
able to bind the activated TGF-β and BMP receptors, competing with R-
Smads and preventing or blocking their activation (Nakao et al, 1997), 
furthermore it is able to binds to all type I receptors via specific lysine 
residues in its MH2 residues (Mochizuki et al, 2004). Although Smad7 
primarily acts at the type I receptor level, it also resides in the nucleus and 
new evidences suggests that it can bind to DNA and to nuclear complexes 
inhibiting Smads transcriptional activity (Zhang et al, 2007). In addition, 
Smad7 is involved in regulation of TGF receptor ubiquitination by smurf 
ubiquitin ligase (Suzuki et al, 2002). The chaperon protein Hsp90 binds to 
TβRII and to TβRI and protects them from ubiquitination by Smurf2, 
contributing positively to TGF-β signaling (Wrighton et al, 2008). Smurf1 
and Smurf2 are HECT-domains containing E3 ubiquitin ligases that 
recognize R-Smads as substrates through a PPXY motif; Smurf2 can bind 
to Smad7, without immediate ubiquitination and degradation, but favouring 
export of Smad7 to the cytoplasm. The complex Smurf-Smad7 is able to 
bind to the TGF-β receptor complex and promotes its ubiquitination, 
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thereby down-regulating signaling; however the activity of Smad7 is 
regulated at many levels: is induced by TGF-β, activin and BMP signaling 
and by ERK (Huo et al, 2007) or inflammatory signals such as interferon-γ, 
TNF-α and interleukin-1β (Bitzer et al, 2000). Activated R-Smads undergo 
ubiquitination and subsequent degradation. Increasing evidence indicates 
that ubiquitin modification is important for regulating components of TGF-
β signaling and can occur in both the basal and the activated state: for 
example, phosphorylated Smad2 is eliminated by the fast action of 
phosphatases but also by the slower action of ubiquitin-dependent 
proteosome degradation. The susceptibility to ubiquitination may be 
controlled by acetylation of the same lysine residues. Following 
phosphorylation, Smad2 and 3 are translocated into the nucleus where 
interact with co-activators and/or co-repressors. Smads transcriptional 
activity is significantly enhanced by recruitment of co-activators and 
histone acetyltransferases, such as p300, C/EBP-binding protein (CBP) and 
p300/CBP-associated factor (P/CAF), which are able to facilitate the 
initiation of transcription (Schmierer et al, 2007). CBP is a co-activator able 
to transfer the acetyl group from acetyl coenzyme A to the lysine residues 
in histones, allowing remodelling of chromatin to a more relaxed 
conformation to allow transcription. Smad2/3 can be acetylated by 
p300/CBP in a ligand-dependent manner enhancing their DNA-binding 
activity in mammalian cells (Simmonsson et al, 2006; Tu et al, 2007). This 
event involves at least three lysine residues, Lys19, Lys20 and Lys39 which 
are required for efficient acetylation of Smad2. in addition, an acetylation 
event is required for Smad2 to mediate activin and TGF-β signaling: 
mutations of the three key lysine residues did not alter the stability of 
Smad2 or its ability to form a complex with Smad4 on promoter DNA, but 
prevent nuclear accumulation of Smad2 and subsequent TGF-β and activin 
responses (Tu et al, 2007). Nuclear Smad7 can be also acetylated by p300 
in two N-terminal lysines, which are also the sites of ubiquitin attachment. 
Acetylation prevented receptor-induced ubiquitination of Smad7 by Smurf, 
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without affecting the subcellular distribution of Smad7. Another Smads 
regulatory process is Sumoylation. In higher eukaryotes are present three 
SUMO (Small-Ubiquitin-like Modifier) proteins, SUMO-1, SUMO-2 and 
SUMO-3, that alter proteins function by creating a composite interaction 
domain (Song et al, 2004) and regulating protein stability and subcellular 
localization. Two sumoylation consensus motifs were observed in Smad4, 
one in MH1 domain and one in the linker region (Song et al, 2004); as 
consequence of this regulation, however, two opposite effects were 
observed, an increase and a decrease of transcriptional activity (Long et al, 
2004; Chang et al, 2005), probably as result of potential competition 
between ubiquitination and sumoylation of the same lysine residue in 
Smad4. Ubiquitination of R-Smad/Smad4 complex can be target of 
proteosome and as a result, gene expression is reduced. By sumoylation, 
ubiquitination effects are blocked, the half life of the activated complex is 
prolonged and gene expression is increased. SUMO modification also 
represses transcriptional activity of a number of transcription factors, such 
as Sp3, c-Jun, c-Myb, AP2, nuclear receptors, Elk-1 and the general co-
activator p300, regulating their biological role (Long et al, 2004). A 
negative regulatory mechanism of Smad signaling can also implicate the 
linker domain phosphorylation; a recent report showed that nuclear GSK3β 
negatively controls TGF-β signaling phosphorylating three distinct Smad3 
linker residues and down-regulating its transcriptional activity, as 
consequence of ubiquitination and proteosomal degradation of Smad3 (Guo 
et al, 2008). Than Smad3 can be phosphorylated in its MH2 domain by 
casein kinase 1 γ2, which leads to the specific ubiquitination and 
degradation of the activated form of Smad3 (Guo et al, 2008b).  
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Figure 4: TGF-β and BMP signaling. A) TGF-β and activin/nodal 
pathway; B) BMP pathway; C) Non-Smad signaling pathways downstream 
of the TGF-β receptors. The nuclear Smad complexes that lead to gene 
regulation are shown for each pathway (Moustakas et al, 2009). 
 
 
 
 
 
 
 
 17 
1.2 Smads and lung diseases 
1.2.1 TGF-β signal transduction pathway 
The transforming growth factor β appears to be the most important cytokine 
involved on stimulation and regulation of lung extracellular matrix (ECM) 
components. Structurally the mammalian TGF-β family is characterized by 
a specific three-dimensional fold and by a conserved number and spacing 
of cystein residues in the C-terminus of the mature polypeptide (Derynck et 
al, 2008). Is possible to observe three prototypic TGF-β isoforms: TGF-β1, 
TGF-β2 and TGF-β3; each of them is encoded by a distinct gene and is 
expressed in both a tissue-specific and developmentally-regulated fashion. 
Specifically, TGF-β1 is expressed in endothelial, haematopoietic and 
connective tissue cells; both TGF-β1 and TGF-β3 are expressed in 
structures undergoing morphogenesis and in mesenchymal cells, while 
TGF-β2 alone is expressed in differentiating and mature epithelium 
(Taipale et al, 1998; Blobe et al, 2000). TGF-β superfamily members are 
involved on regulation of different cellular processes, such as cell growth, 
development, motility, adhesion and apoptosis (Hogan et al, 1996; Mehler 
et al, 1997) and contribute to tissue patterning and regulation and 
differentiation of stem cell self-renewal (De Robertis et al, 2004; Watabe et 
al, 2009). However, the cellular response can be variable and depending on 
the cell type and stimulation context (see Table 1): for instance, was 
observed that TGF-β1 stimulates cellular proliferation in vitro even if it is 
generally considered to be an inhibitor of proliferation and a promoter of 
cellular hypertrophy and differentiation (Choi et al, 1993); whereas was 
observed that it causes epithelial cell apoptosis and growth arrest (responses 
which suppress carcinogenesis) even if it can also induce epithelial-
mesenchymal transition (EMT) and can mediate fibroblast activation 
(responses implicated in promoting carcinogenesis and fibrotic diseases) 
(Siegel et al, 2003). Members of this family are secreted as latent ligands 
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by binding to their pro-peptide, or in trapped form by binding to occluding 
factors. The active form of TGF-β is a dimer stabilized by hydrophobic 
interactions, which in most cases are further strengthened by an inter-
subunit disulfide bridge. As reported previously, TGF-β signal is initiated 
by interacting with and complexing two membrane serine/threonine kinase 
receptors, type I and type II receptors. Ligand binding mediates formation 
of a heterotetrameric complex in which the constitutively type receptor II 
phosphorylates the glycine-serine rich domain in the juxtamembrane region 
of the type I receptor resulting in activation of kinase. The most well 
characterized mechanism whereby TGF-β superfamily members initiate 
signal transduction is via phosphorylation and activation of the Smads 
proteins by the type I receptor (Rahimi et al, 2007). However a number of 
reports also supported the existence of other effector pathways operating 
downstream of TGF-β receptors: the best characterised of these is the c-Jun 
terminal kinase (JNK) family in which activation of JNK by TGF-β can be 
mediated through mitogen-activated protein kinase (MAPK), kinase kinase-
1 and MAPK kinase-4 (Hocevar et al, 1999; Mazars et al, 2000). Ozdamar 
and co-workers described also the pathway that seems to be involved on 
EMT: TβRII phosphorylates the protein PAR6, which regulates the local 
degradation of the RHOA small GTPase that controls the assembly of 
intercellular tight junction in mammalian cells, causing the de-
differentiation known as epithelial-mesenchymal transition (Ozdamar et al, 
2005). In addition TGF-β is able to elicit EMT via Smad signaling, leading 
to the transcriptional induction of the major inducers of this differentiation 
process (Thuault et al, 2008). In a distinct mechanism TβRI phosphorylates 
both serine and tyrosine residues in the SHCA (SHC1) adaptor; causing the 
activation of the Ras-Raf-MEK-ERK mitogen-activated protein kinase 
signaling cascade which can regulate cell proliferation and migration (Lee 
et al, 2007); as a final example, the tyrosine kinase Src can phosphorylate 
Tyr284 in the cytoplasmatic domain of the TβRII, leading to GRB2 and 
 19 
SHC recruitment and to the activation of the p38 MAPK pathway (Galliher 
et al, 2007).  
 
 
 
 
 
 
Endothelium Epithelium Fibroblasts 
   
Migration 
Morphogenesis1 
Growth control2 
Cell cycle arrest 
Apoptosis1, 2,3 
Adhesion 
ECM production4 
Cytokine production 
Growth control2 
EMT5 
ECM production4,6 
Proliferation7,8,9 
Cytokine secretion 
Anchorage-
independent growth10 
Growth arrest2,11 
 
 
Table 1: TGF-β regulatory effects on target cells (Magno et al, 2008). 
 
1) Siegel, 2003; 2) Massaguè, 2006; 3) Ramjaun, 2007; 4) Shi-Wen, 2006; 5)Rahimi, 
2007; 6) Holmes, 2001; 7) Strutz, 2001; 8) Khalil, 2005; 9) Pelaia, 2007; 10)Anzano, 
1997; 11) Datto, 1999. 
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1.2.2 Cross-talk between MAPKs and Smads signaling pathway for TGF-β 
Several studies reported a cross-talk between kinases and members of Smad 
family and demonstrated that activation of p38 MAP kinase (Kamaraju et 
al, 2005) and ERK MAP kinase (Hayashida et al, 2003) may augment 
Smad signaling. Indeed MAPKs are able to bind the consensus sites in the 
linker region and are responsible of Smad2/3 phosphorylation and/or 
Smad4 activation (Derynck et al, 2003; Hayashida et al, 2003). In vitro, 
ERK1 and 2 are able to activate Smad1, 2 and 3 and attenuate the nuclear 
accumulation and signaling activity of these proteins in response to agonists 
(Kretzschmar et al, 1999) and chemical inhibitors (Rhyu et al, 2005); 
several studies demonstrated that the use of ERK and JNK inhibitors 
inhibited TGF-β1-stimulated activation of Smad2/3 in human airway 
smooth muscle ASMC cells (Shaoping et al, 2005) and that the ERK 
inhibitors, PD98059 and UO126, were able to inhibit promoter region and 
to reduce Smad3 protein expression in both, human alveolar type II 
epithelial adenocarcinoma A549 cell line and ASMC (Ross et al, 2007). 
However, the interaction between ERK and Smads could alter signaling in 
either positive and negative manner in according to the cell type studied: 
actually, human cells of mesenchymal origin appear to show synergy in 
ERK-Smad interaction whereas epithelial cells generally appear to show 
inhibition (Hayashida et al, 2003). Recently Hou suggested for the first 
time that Smad7 plays an important role in the signal cascade transition 
mechanism between the TGF-β1-mediated Smads and ERK MAP kinases 
signaling pathways (Huo et al, 2007); the author demonstrated that in 
human bronchial epithelial BEP2D cell line Smad7 is required for TGF-β1-
induced activation of ERK and that this activation can be attenuated by the 
silencing of Smad3 and Smad4 genes, indicating that gene transcription of 
Smad7, driven by TGF-β1, is required for Smad3 and Smad4 expression. 
Imamichi and colleagues also reported that induction of focal complex 
formation in epithelial cells by TGF-β1 is mediated by activated ERK and 
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JNK MAP kinases and is independent from Smad4 (Imamichi et al, 2005); 
moreover Engel demonstrated that the JNK pathway is able to reinforce 
Smads signaling by permissive phosphorylation of Smad3 (Engel et al, 
1999), while Goldberg demonstrated that overexpression of type II 
transforming growth factor-beta receptor is able to activate ERK and JNK 
MAP kinases in human fibroblasts (Goldberg et al, 2002). 
 
1.2.2 Smads as mediators of TGF-β-induced diseases 
Fibrosis 
Destruction of the TGF-β signaling system has been implicated in 
embryonic anomalies (Chang et al, 1999, 2000; Galvin et al, 2000; Yang et 
al, 1999), cancer and tumorigenesis (Oshima et al, 1996; Dijke et al, 2002, 
Rahimi et al, 2007), autoimmune disease (Oshima et al 1996; Zhu et al, 
1998; Yang et al, 1999; Ashcroft et al, 1999), atherosclerosis (Grainger et 
al, 1995a, 1995b, 1999), hypertension (Cambien et al, 1996), osteoporosis 
(Langdahl et al, 1997), fibrotic diseases (Blobe et al, 2000; Barànek et al, 
2002) and hereditary hemorrhagic telangiectasia (Johnson et al, 1996; 
Gallione et al, 1998). The destruction of the TGF-β signaling system has 
been also shown to be involved on different pulmonary diseases such as 
COPD and principally pulmonary fibrosis. Injury of lung tissue leads to 
induction of TGF-β, which limits some inflammation reactions and is 
involved in mediating fibrotic tissue remodelling by increasing the 
production and decreasing the degradation of connective tissue and by 
mediating the normal tissue repair (Sporn et al, 1992). Several authors 
considered TGF-β as a marker of activity of tissue repairing and 
remodelling, actually as acute as well as chronic lung disease showed an 
increase of TGF-β protein and mRNA expression during the phase of tissue 
remodelling (Broekelmann et al, 1991; Elssner et al, 2000). The direct 
involvement of TGF-β in fibrosis comes from several studies of fibrotic 
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disease. The prominent hypothesis of pulmonary fibrosis development is 
that it is caused by chronic inflammation in response to an unknown 
etiologic agent which leads to tissue destruction, to ongoing wound healing 
responses and fibrosis (Bonniaud et al, 2005). TGF-β is a critical element 
of progression from inflammation to chronic fibrosis: the pro-fibrotic 
effects of TGF-β are numerous, including induction of myofibroblasts, 
increase of matrix synthesis and inhibition of collagen breakdown. 
Different studies demonstrated that TGF-β is involved in EMT by 
stimulating myofibroblasts transdifferentiation (Siegel et al, 2003; Zeisberg 
et al, 2007). The hallmarks of EMT include the destruction of cell-cell and 
cell-matrix interactions, degradation of the surrounding ECM and actine 
reorganization. However if EMT is a normal physiological process 
necessary for proper development, the pathological induction is associated 
with carcinoma and fibrotic disease (Lee el al, 2006; Radisky et al, 2007). 
Most of these effects are mediated through the Smad signaling pathway and 
even if several studies demonstrated a requirement for Smad4 in TGF-β-
mediated EMT (Valcourt et al, 2005; Medici et al, 2006) Smad3 seems to 
be principally related to the fibrotic phenotype. Smad3 pathway is involved 
in pathogenic mechanisms mediating tissue destruction (lack of repair) and 
fibrogenesis (excessive repair); TGF-β stimulates myofibroblasts 
transdifferentiation through Smad3-dependent and -independent signals, 
contributing to the excessive matrix deposition which characterizes 
obliterative bronchiolitis. Recently was demonstrated that Smad3 null mice 
are protected from progressive fibrosis mediated by overexpression of 
TGF-β1 (Bonniaud et al, 2004), they do not develop lung fibrosis induced 
by bleomycin and are protected against radiation-induced fibrosis of the 
skin (Zhao et al, 2002). Experiments in vivo demonstrated that 
administration of active TGF-β to mice deficient in Smad3 blocks the 
ability of TGF-β to induce matrix and enzyme inhibitory gene expression 
and also matrix accumulation without any progress to scar formation or 
fibrosis (Gauldie et al, 2007). This indicates that TGF-β and Smad 
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signaling pathway, specifically Smad3, are required to initiate fibrosis and 
that the TGF-β-induced mechanism is prominent in this disease. Lost of 
Smad3 was shown to confer resistance to fibrosis and results in reduced 
inflammatory cell infiltrates, reduced autoinduction of TGF-β, important to 
sustain the process, and reduced elaboration of collagen. Recently 
Higashiyama showed that treatments with the inhibitor of activin receptor-
like kinase 5 (ALK5), a type I receptor of TGF-β, significantly attenuated 
Smad2/3 nuclear translocation and decreased myofibroblasts proliferation 
and collagen type I deposition suggesting that ALK5 inhibition is able to 
attenuate R-Smads activation and thereby pulmonary fibrosis (Higashiyama 
et al, 2007). Than a significant reduced Smad3 protein expression was 
observed in cystic fibrotic epithelial cells of nasal epithelium and in mouse 
models, a reduction that was apparently sufficient to influence the 
transmission of TGF-β signals, including anti-inflammatory signals. 
(Kelley et al, 2001).  
 
COPD and asthma 
Lung tissue remodelling and airway fibrosis play an important role in the 
development of symptoms associated with lung function and loss in asthma 
and in chronic obstructive pulmonary disease (COPD). Less is know about 
the direct involvement of Smad proteins on COPD even if various studies 
demonstrated that TGF-β is involved in airways remodelling which 
characterize this disease. Increased levels of TGF-β1 protein and mRNA 
were observed in the bronchial and alveolar epithelium of COPD patients 
and correlated with the number of intraepithelial macrophages (De Boer et 
al, 1998); similarly elevated levels of TGF-β1 were found in the bronchial 
epithelium of smokers with COPD compared with healthy smokers (De 
Boer et al, 2000). Immunohistochemistry analysis demonstrated that 
cigarette smoke is able to down-regulate the transcription of inhibitory 
Smad6 and 7 in the bronchial mucosa of Severe COPD patients (Springer et 
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al, 2004), in the same way, a reduced Smad7 mRNA expression was 
observed in bronchial biopsies of Mild/Moderate COPD patients in 
comparison with controls; in contrast, any significative change was 
observed for Smad3 and Smad4. As demonstrated in a mouse model, 
increased presence of TGF-β1 in the parenchyma may protect against 
emphysema, whereas the absence of proper Smad3 signaling results in an 
ineffective repair response to damages in the lung, in a reduction of 
suppression of expression of matrix metalloproteinases (MMPs), in more 
susceptibility to airspace enlargement and in development of emphysema. 
Recently was demonstrated that Smad3-deficient animals are protected 
from fibrosis even if appear more susceptible to emphysema: Smad3-null 
mice were resistant to both bleomycin- and TGF-β-mediated fibrosis, but 
developed spontaneous age-related airspace enlargement, consistent with 
emphysema, and lacked the ability to repair tissue damage appropriately 
(Gaudie et al, 2006).  
Studies on human asthma showed increased levels of TGF-β1 and its 
transductor factors in the airways (Redington et al, 1997). Airway 
remodelling is one of the hallmark features of asthma. TGF-β appears to be 
implicated in ECM proteins deposition which characterize asthma, and 
especially in deposition of collagen. TGF-β1 levels were significantly 
higher in bronchial submucosa of asthmatics if compared with subjects with 
COPD (Kokturk et al, 2003) and concentration of active form of TGF-β1 
were higher in bronchoalveolar lavage fluid (BAL) of patients with Severe 
asthma compared with controls (Redington et al, 1997). Runyan and 
colleagues found a cross talk between Smads and Phosphoinositide 3-
kinase (PI3K) pathway that enhanced TGF-β-induced collagen type I 
expression in human mesangial cells (Runyan et al, 2004). Recently was 
also observed a different Smad2 activation between asthmatic and non-
asthmatic airway smooth muscle ASMC cells with levels of phosphorylated 
Smad2 significantly higher in the asthmatic cells in comparison with the 
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non-asthmatic (Runyan et al, 2004). In addition expression levels of Smad7 
in bronchial epithelial cells of asthmatics were found to be inversely 
correlated with basement membrane thickness and airway 
hyperresponsiveness in asthmatic subjects, suggesting an active 
remodelling process resulting in a thickened of basement membrane 
(Johnson et al, 2006).  
 
1.3 New perspectives for CCL5 in lung diseases 
Chemokines are a family of proinflammatory cytokines that act through cell 
surface receptors to regulate numerous routine physiological and 
phatophysiological processes, such as haematopoiesis, T-cell activation, 
angiogenesis and inflammatory disease, as well as HIV-1 infection 
(Hasegawa et al, 2001; Stantchev et al, 2001). Characterized by the 
presence of two disulphide bonds formed between four conserved cystein 
residues, chemokines are classified into four subfamilies according to the 
pattern of conserved cysteines in their amino acid sequences: twenty-six 
CC chemokines, seventeen CXC chemokines, two C chemokines and one 
CX3C chemokine (Gale et al, 1999; Murphy et al, 2000). MIP-1α 
(Macrophage Inflammatory Protein-1α), RANTES also termed CCL5 
(regulated upon activation, normal T-cell expressed and presumably 
secreted) and MCP-1 (Monocyte Chemotactic Peptide-1) are members of 
CC chemokines subfamily and are chemotactic and activator factors for 
monocytes, basophils, eosinophils and neutrophils (Alarm et al, 1993; 
Capelli et al,1999; Magno et al, 2007; Yoshikawa et al, 2007). Several 
studies demonstrated an involvement of these chemokines pulmonary 
disease, such as fibrosis and COPD: MIP-1α and MCP-1 were identified as 
pro-fibrotic mediators, actually studies in the bleomycin model of 
pulmonary fibrosis showed that anti-MIP-1α antibodies, and similarly 
inhibition of MCP-1, could significantly reduce the development of this 
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disease (Smith et al, 1994; Belberio et al, 2001). Recently, we observed that 
in bronchial biopsies of Severe COPD there is an increase of NAP-2 and 
CCL5 that could explain the sustaining neutrophilia observed in airways of 
these patients (Magno et al, 2007); in addition, we demonstrated that in 
bronchial biopsies of COPD patients, levels of CCL5 immunostained cells 
were 2-15 times higher than those of other chemokines analyzed and that in 
the bronchial mucosa of Severe COPD the expression of CCL5 mRNA and 
the number of CCL5+ cells was significantly increased if compared with 
controls (Di Stefano et al, 2009). These results augment data in literature 
for which increased levels of CCL5 were observed in sputum and in BAL 
of patients with stable COPD (Miller et al, 2007; Costa et al, 2008). 
Moreover high level of this chemokine were observed in other pulmonary 
diseases: in asthmatics was observed an increase of CCL5 protein 
expression, and similarly, CCL5 protein levels appear to be higher in 
epithelium of patients with an exacerbation of chronic bronchitis (Chung et 
al, 2001) (Table 2). However the role performed by CCL5 in these diseases 
is not completely clear and needs more study.  
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±++IL-4
?+IL-3
±++IL-5
ASTHMA COPD
IL-10 + or – ?
IL-13 + ?
Eotaxin ++ ++
RANTES ± ++*
MCP-1 ? +
IL-8 ± ++
IL-1ß ? +
TNF-α + +
TGF-ß + +
EGF ± +
 
 
Table 2: Expression of cytokines in asthma and in COPD (Chung et al, 
2001). * during exacerbation; - reduced; + small increase; ++ large 
increase; ? not known or uncertain; ± no change or negligible.  
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OBJECTIVE 
Destruction of the TGF-β signaling system has been implicated in several 
diseases. Recently it was considered the role of this growth factor in 
development of lung pathologies such as COPD and pulmonary fibrosis. 
The pro-fibrotic stimuli of TGF-β are numerous, including induction of 
myofibroblasts, EMT and regulation of extracellular matrix components, 
such as collagen, essential for tissue homeostasis and function. The 
extensive family of “COL” gene products is composed at least of 16 chain 
types, including fibril-forming interstitial collagens (type I, II, III and V) 
and basement membrane collagens (type IV). Type I collagen and ECM 
accumulation is one of the hallmarks of fibrosis (Verrecchia et al, 2002). It 
was demonstrated that Smad signaling pathway, and specifically Smad3, is 
required to initiate fibrosis induced by TGF-β. Indeed, loss of Smad3 was 
shown to confer resistance to fibrosis and results in reduced inflammatory 
cell infiltrates, reduced auto-induction of TGF-β and reduced elaboration of 
collagen; furthermore, as observed in dermal fibroblasts, Smad3 signal 
pathway is considered crucial for simultaneous activation of several 
fibrillar collagen gene promoters induced by TGF-β (Verrecchia et al, 
2001). At one time it was thought that all collagens were secreted in 
connective tissue by fibroblasts, but now we know that numerous epithelial 
cells make certain types of collagens (Ward et al, 2005) playing a crucial 
role in the development of fibrotic disease.  
On the bases of these information, the aim of this study has been: first, to 
set up an opportune in vitro experimental model to analyze if Smads could 
be abnormally expressed in the human bronchial epithelial cells after TGF-
β1 stimulus, to value the involvement of epithelium in the collagen 
production. Second, to analyze Smads and collagen type I expression in 
bronchial biopsies of COPD patients, to understand their possible 
involvement in chronic obstructive pulmonary disease and third, according 
to the increased CCL5 levels recently observed in the bronchial mucosa of 
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Severe COPD, the aim was to check the effects of CCL5 in TGF-β/Smads-
dependent collagen production to understand its possible involvement in 
the pathogenesis of COPD. 
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MATERIALS & METHODS 
3.1 In vitro experiments  
3.1.1 Cell culture 
SV40-transformed human bronchial epithelial 16HBE cell line was used to 
setting an in vitro model in order to assess their behaviour after TGF-β 
stimulation. Cells were grown in Dulbecco's modified Eagle's medium 
(DMEM) supplemented with 10% foetal calf serum (FCS), 100 U/ml 
penicillin, 100µg/ml streptomycin, 0.25µg/ml amphotericin B and 2mM of 
L-glutamine (all from Invitrogen). They were maintained at 37°C in a 
humidified atmosphere of 5% CO2 and media was replaced every two days 
until 80% confluence. For RNA and protein extraction, cells were cultured 
in 6-well culture plates and 25cm2 tissue culture flasks (Corning), 
respectively, while for immunocytochemical analyses cells were plated in 
8-well chamber slides (BD Biosciences). Experiments were performed 
using cells at passages 12-19. 
 
3.1.2 TGF-β1 and CCL5 treatments 
After reaching 80% confluence, the incubation medium was changed to 
serum-free DMEM, supplemented with 100U/ml penicillin, 100µg/ml 
streptomycin, 0.25µg/ml amphotericin B and 2mM L-glutamine for 24h. 
Then cells were stimulated with 1ng/ml and 10ng/ml of Recombinant 
Human TGF-β1 (R&D System), with 10ng/ml of Recombinant Human 
RANTES/CCL5 (R&D System) and 10ng/ml of both TGF-β1 and CCL5, 
diluted opportunely in serum-free DMEM. Exposure of cells was carried 
out with incubation times of 0, 3 and 24 hours. Comparative dose-
dependent experiments were done in triplicate, while experiments for TGF-
β1 and CCL5 were repeated six times with cells at different passages. 
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3.1.3 MAPKs inhibitor treatments 
To check MAPKs involvement in both TGF-β1 and TGF-β1/CCL5-induced 
effects, cells were pre-treated for 30 minutes with 3µM of SP600125, 5µM 
of PD059098 and 3µM of SB203580, selective inhibitors of JNK, ERK and 
p38, respectively (all from Calbiochem). Then a new medium with TGF-β1 
and CCL5 was added to cell as previously described. Experiments were 
performed in triplicate with results comparison to cells not treated with 
inhibitors. 
 
3.1.4 Real Time quantitative RT-PCR 
Total RNA was extracted using RNeasy kit from Quiagen following the 
manufacturer’s instructions. Reverse transcription was carried out with 
superscript RT after DNase I digestion (both from Promega) according to 
the manufacturer’s protocols. 1µg of RNA was used for Real Time 
quantitative RT-PCR analysis only if the absorbance ratio (A260⁄A280 ratio) 
was > 1.6. Quantitative measurement of transcripts was performed using 
the QuantiTect SYBR Green PCR kit (Quiagen) and Rotor-Gene6 RG-3000 
detection system (Corbett) according to the manufacturer’s protocol. 
Amplification of human glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) was performed as internal standard. Specific primers pair were 
used for Smads (Sigma Aldrich) and for collagen type I and GAPDH 
(Invitrogen):  
Collagen Type I Forward: 5’-CCTGGATGCCATCAAAGTCT-3’ 
Reverse: 3’-TCTTGTCCTTGGGGTTCTTG-5; 
                    Smad3   Forward: 5’-CTGCGTGAATCCCTACCACT-3’ 
                                 Reverse: 3’-GGATGGAATGGCTGTAGTCG-5’; 
                    Smad4   Forward: 5’-ATCGTGCATCGACAGAGACA-3’ 
                                  Reverse: 3’-TACTGGCAGGCTGACTTGTG-5’; 
                    Smad7   Forward: 5’-GTGGCATACTGGGAGGAGAA-3’ 
                                  Reverse: 3’-TTGTTGTCCGAATTGAGCTG-5’; 
                    GAPDH  Forward: 5’-CAATGACCCCTTCATTGACC-3’ 
                                    Reverse: 3’-GACAAGCTTCCCGTTCTCAG-5’ 
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The cycling conditions were: 95 °C for 15 min, followed by 40 cycles of 95 
°C for 20 s, 60 °C for 30 s, Tm for each primer and 72 °C for 25 s. The 
results are presented as the relative expression calculated from the δδ-Ct-
values. 
 
3.1.5 Cell viability assay (MTT) 
Cell viability after TGF-β1 and both TGF-β1/CCL5 exposure was 
evaluated by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide] assay (Sigma Aldrich). MTT is a yellow water-soluble 
tetrazolium dye which is reduced in living cells to a water-insoluble dark 
blue formazan precipitate by a mitochondrial dehydrogenase enzyme. After 
treatments for 0, 3, 24 in 24-culture well plates, culture medium was 
replaced by MTT previously diluted in phenol red-free DMEM. After an 
incubation period of 4 hours, the solubilisation of the precipitate from cells 
was accomplished by using acid absolute isopropanol (HCl 0.04M). The 
amount of formazan was therefore determined spectrophotometrically by 
reading A570 with background subtraction at 650nm. DMSO 1% was used 
as positive control to check cytotoxicity. Triplicate assays were performed 
using cells at different culture passages. cells not-exposed to treatments 
were used as controls. 
 
3.1.6 Total and sub-fractionated protein extraction 
16HBE cells were collected after treatments. In order to obtain total 
proteins, cells were lysed with a lysis buffer (20mM Tris/HCl pH 7.5, 1% 
Nonidet P-40, 50mM NaCl, 1x Proteases Inhibitor). In parallel 
experiments, nuclear and cytoplasmatic proteins were sub-fractionated 
using Nuclear Extraction Kit (Active Motif) following the manufacturer’s 
protocol. Quantitative measurement of proteins was performed using the 
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DC Protein Assay kit (Bio-Rad), following manufactures’ instructions and 
determined spectrophotometrically by reading at A750.  
 
3.1.7 SDS-PAGE and Immunoblotting 
30µg of total or sub-fractionated proteins were resolved by SDS-PAGE and 
transferred to nitrocellulose membranes (Millipore). After blocking in 5% 
milk no-fat in phosphate-buffered saline (PBS) containing 0.05% Tween-
20, membranes were incubated with appropriated antibodies diluted in 3% 
Bovine Serum Albumin (BSA) in T-PBS 0.05% Tween-20, overnight at 
4°C. Specifically, to analyze nuclear fraction, membranes were incubated 
with anti-phospho-Smad3 at 1: 2000 dilution (rabbit polyclonal, Abcam) 
and anti-Lamin A/C at 1:600 dilution (mouse monoclonal, SantaCruz 
Biotechnology), while total proteins membranes were incubated with anti-
Smad3 at 1:200 dilution (rabbit polyclonal, Abcam), anti Smad7 at 1:1000 
dilution (mouse monoclonal, Abcam) and anti-β-Actin at 1:2000 dilution 
(mouse monoclonal, SantaCruz Biotecnology). The second day membranes 
were washed six times with T-PBS 0.05% Tween-20 and incubated with 
horseradish peroxidase-coupled secondary antibodies (anti-mouse and anti-
rabbit, 1:10000 and 1:50000, respectively) for 1 hour at room temperature. 
After washing, the blots were visualized with ECL plus western blotting 
detection reagents (GE Healthcare). 
 
3.1.7 Immunocytochemical staining for assessing phospho-Smad3 
In order to asses phosphor-Smad3 localization immunocytochemistry (ICC) 
analysis was performed on 16HBE cultured and treated in 8-well chamber 
slides (BD Falcon). After culturing, cells were washed with PBS and fixed 
in methanol for 20 minutes at -20°C. Air-dried slides were then stored at -
20°C until use. For ICC procedure, the cells were permeabilized with 0.1% 
Triton X-100 in PBS (Sigma Aldrich) and then washed with PBS. To block 
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endogenous peroxidases, cells were treated with 0.3% H2O2 in PBS and 
then with 1% FBS for blocking aspecific antigens. Antibody anti-p-smad3 
(rabbit monoclonal, Abcam) was used at 1:250 dilution. Antibody anti-
cytokeratin 8 (mouse monoclonal, Sigma Aldrich) was used at 1:200 
dilution as positive control. Negative controls were obtained substracting 
the primary antibody incubation step. The detection system used was the 
LSAB (Labelled Streptavidin-Biotin)-2 kit (Dako), an avidin-biotin 
complex system in which a biotinylated secondary antibody reacts with 
peroxidase-conjugated streptavidin molecules. The 3-amino-9-
ethylcarbazole (AEC+ High Sensitivity Substrate Chromogen Ready-to-
use, DakoCytomation) was used as developer. Each passage was preceded 
by washes with PBS. The positive reaction was observed using a light 
microscope (Leica DM 5000B). Percentage of positive cells was evaluated 
at 20x and 40x magnification. 
 
3.1.9 Statistic analysis 
Data obtained from the evaluation of the immunoreactivity, as well as from 
Real Time-PCR densitometry, were plotted using Microsoft Excel software 
(Microsoft, Redmond, WA, USA). Statistical analyses were carried out 
using GraphPad Prism 4.0 package (GraphPad Inc., San Diego, CA, USA) 
and were performed using non-parametric tests in order to compare groups 
that did not fit the normal distribution. To evaluate the significance of 
difference between all groups the Mann-Whitney U test was used. Standard 
deviation of values was considered for each group of samples. Data were 
considered significant for p<0.05. To confirm the statistical results 
obtained, each experiment was repeated six times using different passages.  
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3.2 Experiments in vivo 
3.2.1 Subjects 
All subjects were recruited from the Section of Respiratory Medicine of the 
Salvatore Maugeri Foundation (Veruno, Novara). Table 3 shows the 
clinical characteristics of the subjects recruited. The severity of the airflow 
obstruction was staged according to the GOLD criteria: GOLD stage I = 
Mild, Stage II = Moderate, Stage III = Severe and Stage IV = Very Severe 
COPD (GOLD 2006). Data are presented as mean (SEM).  
 
42 (3)33 (3)30 (2)13Severe/Very Severe 
COPD
60 (2)72 (4)66 (4)12Mild/Moderate COPD
82 (2)ND107 (4)13Healthy Smokers
85 (3)ND115 (4)11Healthy non Smokers
FEV1/FVC%FEV1 post
(% pred)
FEV1 pre 
(% pred)
NumberSubject
 
Table 3: Criteria used for recruiting of COPD patients. FEV1= Forced 
Expiratory Volume in 1 second; FEC =Forced Vital Capacity 
 
3.2.2 Fiberoptic bronchoscopy, collection of bronchial biopsies 
 
A standardised procedure (Di Stefano et al, 1998) was followed for 
fiberoptic bronchoscopy and collection of bronchial biopsies. All subjects 
were premedicated intramuscularly with 0.5mg of atropine and 10mg of 
diazepam and orally with 10mg of dihydrocodein. Nares and oropharinx 
were anesthetized topically with 10% lidocaine before bronchoscopy. 
Bronchoscopy was performed with a flexible fiberoptic bronchoscope 
(Pentax FB-18P; Asahi Optical Co. LTD) in all subjects. Bronchial biopsies 
were taken through the bronchoscope with standard forceps from the 
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subcarina of a basal segment bronchus of the right lower lobe. From this 
area two specimens were obtained in each subject. Biopsy specimens were 
gently extracted from the forceps and processed for light microscopy. 
Samples were embedded in OCT and frozen at -80°C. The best specimen 
was then oriented and serial sections 4µm thick were cut. Two sections at 
an interval of 100µm were then appropriately stained. 
 
3.2.3 Immunohistochemistry 
For immunohistochemistry (IHC) procedure, serial sections were fixed with 
4% of formaldehyde or acetone (according to the instruction relative to the 
primary antibody to used), and washed with a wash solution (Tris Maleato 
0,05M, saponin 0,1% pH 7,6). To enhance the detection, tissue sections 
were firstly incubated with avidin and than incubated with biotin both for 
20 minutes. To block non specific reactive antigens, sections were 
incubated for 20 minutes with normal serum diluted 1:20 in wash solution 
and stained for 2 hours with specific primary antibodies diluted in wash 
solution too (see Table 4); than were incubated with secondary antibodies 
(anti-mouse 1:200, anti-rabbit 1:200 and anti-goat 1:200, all from Vector). 
The detection system used was the LSAB (Labelled Streptavidin-Biotin)-2 
kit (Dako), an avidin-biotin complex system in which a biotinylated 
secondary antibody reacts with peroxidase-conjugated streptavidin 
molecules. The fast-red substrate (Sigma Aldrich) was used as developer. 
Each passage was preceded by washes with the wash solution. Control 
slides were included in each staining run using human tonsil as a positive 
control. The positive reaction was observed using a light microscope (Leica 
DC 300F). Percentage of positive cells was evaluated at 400x and 600x 
magnification. 
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Table 4: Primary antibodies used for IHC analysis. 
 
3.2.4 Scoring system for immunohistochemistry 
Light-microscopic analysis was performed at magnification of 630x. All of 
the positive cells in bronchial submucosa were quantified in the area 100µm 
beneath the epithelial basement membrane with the use of a graded bar 
mounted at ocular level in several non-overlapping high power fields until 
all of the available area was covered. The final result, expressed as the 
number of positive cells per square millimetre, was calculated as the 
average of all of the cellular counts performed in each bronchial biopsy. 
The final result was expressed as the average of all scored fields performed 
in each biopsy. The immunostaining was also scored using a range from 0 
(absence of immunostaining) to 3 (extensive intense immunostaining) in 
the bronchial epithelium. A mean ± standard deviation of 0.620 ± 0.220µm 
of epithelium was analyzed in COPD and control subjects. 
 
Primary antiboby Code product dilution Fixative solution 
Collagen type I Sigma Aldrich 
mouse monoclonal 
1:100 acetone 
Smad3 Zymed  
rabbit polyclonal 
1:25 formaldehyde 
P-Smad2/3 Santa Cruz  
Goat polyclonal 
1:100 formaldehyde 
Smad2 Zymed  
rabbit polyclonal 
1:25 formaldehyde 
P-Smad2 Upstate  
Rabbit monoclonal 
1:150 formaldehyde 
Smad7 Santa Cruz  
rabbit polyclonal 
1:25 formaldehyde 
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3.2.5 Statistical analysis 
Group data were expressed as means ± standard error for functional data or 
median (range) for morphologic data. Differences between groups were 
analyzed by using ANOVA for functional data. The ANOVA test was 
followed by the unpaired t test for comparison between groups. The 
Kruskall-Wallis test applied for morphologic data was followed, when 
significant, by the Mann-Whitney U test for comparison between groups. 
Correlation coefficients were calculated by using the Spearman rank 
method. Probability values of p<0.05 were considered significant. 
Statistical analyses were carried out using GraphPad Prism 4.0 package 
(GraphPad Inc., San Diego, CA, USA). 
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RESULTS & DISCUSSION 
TGF-β1 time/dose-induced effects on collagen type I mRNA expression  
Evaluation of results obtained in three independent sets of experiments 
showed that cell exposure to increasing doses of TGF-β1 (1, 2.5, 5 and 
10ng/ml) induced a dose-dependent enhancement of collagen type I mRNA 
expression after 24 hours in human bronchial epithelial cells, with 
significative values for 5ng/ml and 10ng/ml (p=0.0130 and p=0.0017, 
respectively) (Figure 5). Furthermore, treatments for different time of 
exposure demonstrated that TGF-β1 was also able to increase in a time-
dependent manner collagen type I transcription: specifically we observed 
that with respect to control, 1ng/ml of TGF-β1 caused a rapid significant 
increase after 3 hours of exposure (p=0.0190) (Figure 6), whereas treatment 
with 10ng/ml caused a significant increase at 24h (p<0.0001), suggesting a 
time and dose-dependent TGF-β1-induced effect on collagen type I mRNA 
in 16HBE (Figure 7). 
 
TGF-β1-induced effects on Smads mRNA and protein expression  
 
In order to investigate the involvement of Smads on the collagen type I 
stimulation observed previously, we valued the effects of treatments on 
Smads mRNA and protein expression. Our results confirmed data in 
literature (Yanagisawa et al, 1998): actually in 16HBE treated with 1ng/ml 
of TGF-β1 we observed a time-dependent decrease of Smad3 mRNA 
expression with a significant reduction at 24h (p=0.0207) if compared with 
controls; furthermore, analysis of Smad4 and Smad7 transcription levels 
revealed that the treatment caused initially an increase of Smad7 mRNA 
(p=0.0043), maybe to balance the enhancing of activated p-Smad3 
observed into the nucleus (see below) and a reduction of both Smad7 and 
Smad4 mRNA at 24h (p=0.0087and p=0.0381, respectively) (Figure 8). 
These results let us hypothesize that in 16HBE, treatment with 1ng/ml of 
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TGF-β1 do not alter the regulatory role of the inhibitor Smad7 which is 
able to balance the increase of p-smad3 and interfere with the induced-
collagen production. In contrast, treatment with 10ng/ml of TGF-β1 caused 
a significant enhance of both Smad3, Smad4 and Smad7 mRNA 
transcription at 24h with respect to controls (p=0.0472, p=0.0433 and 
p=0.0422, respectively) (Figure 9) and a significant time-dependent 
increase of Smad3 phosphorylation (p=0.0159 at 3h and p=0.0286 at 24h) 
(Figure 10, A). In addition, in order to provide a quantitative confirmation 
to the transcriptional data observed previously we performed a semi-
quantitative western blot: through the statistical analysis of both 
cytoplasmatic and nuclear fraction, we observed an enhancing of p-Smad3 
into the nucleus after treatment with 1ng/ml of TGF-β1 (Figure 10, B-D1) 
while a significant increase of nuclear phospho-Smad3 protein expression 
was observed at both 3 hours (p=0.0079) and 24 hours (p=0.0079) (Figure 
10, C-D2) after treatment with 10ng/ml of TGF-β1. These results suggested 
a TGF-β1-induced nuclear translocation of activated Smad3 and thereby its 
involvement in collagen type I transcription. 
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Figure 5: TGF-β1-dose-dependent collagen type I mRNA expression 
after 24h of exposure. 
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Figure 6: Time-dependent collagen type I mRNA expression after  
treatment with 1ng/ml of TGF-β1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Time-dependent collagen type I mRNA expression after 
treatment with 10ng/ml of TGF-β1.  
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Figure 8: Smads mRNA expression after treatment with 1ng/ml of 
TGF-β1. A) Smad3 mRNA; B) Smad4 mRNA; C) Smad7 mRNA. 
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Figure 9: Smads mRNA expression after treatment with 10ng/ml of 
TGF-β1. A) Smad3 mRNA; B) Smad4 mRNA; C) Smad7 mRNA. 
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Figure 10: Effects of TGF-β1 on p-Smad3 protein expression. A) Smad3 
phosphorylation level after 10ng/ml of TGF-β1; B-D1) Western blot results 
for nuclear p-Smad3 after 1ng/ml of TGF-β1; C-D2) Western blot results 
for nuclear p-Smad3 after 10ng/ml of TGF-β1. 
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Immunohistochemical expression of TGF-β1, collagen type I and 
Smads in bronchial epithelium of COPD patients 
In order to assess the contribution of the bronchial epithelium in inducing 
collagen type I production in patients with COPD we evaluated the 
expression of TGF-β family members and collagen type I, in both the 
mature and pro- form, by immunohistochemical analysis (Figure11, B). All 
of the positive cells in the epithelium were quantified using a range from 0 
(absence of immunostaining) to 3 (extensive intense immunostaining) and 
the results were statistically analyzed to assess significance of variation of 
expression with respect to positive controls (Kruskall-Wallis test) and 
between groups (Mann-Whitney U test). No significant changes were 
observed for collagen and pro-collagen type I between the four groups of 
subjects investigated in the bronchial epithelium. In contrast, when 
assessing the expression of members of the transforming growth factor 
family and their receptors, we observed a significant increase only for TGF-
β1 in Mild/Moderate COPD compared with control healthy smokers 
(p<0.05, Mann-Whitney U test; p=0.054, Kruskall-Wallis test). Similarly, 
Smads immunostaining revealed no significant variation between all the 
four groups of subjects analyzed (Table 5). These results confirmed the low 
level of collagen deposition observed in the bronchi of COPD patients, 
hallmark of this pulmonary disease, and open a new perspective to 
investigate the molecular mechanism that inhibits the pro-fibrotic stimulus 
induced by TGF-β1. Furthermore, the IHC results obtained for Smads 
demonstrated that Smad3 levels are not substantially increased in human 
bronchial epithelium, suggesting, as expected by our results, a modest 
involvement of this molecule in sustaining the pro-fibrotic process in the 
bronchi of these patients.  
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Immunohistochemical expression of TGF-β1, collagen type I and 
Smads in bronchial submucosa of COPD patients 
TGF-β2 and TGF-β3 immunostaining levels were the two most relevant 
observed in this study. Specifically, counting positive cells in the area of 
100 mm beneath the epithelial basement membrane, the number of TGF-
β2+ cells in the bronchial submucosa of Mild/Moderate COPD was 
significantly lower than in control healthy smokers (42.5 (range 0.0-320.0), 
p<0.05); similarly the number of TGF-β3+ cells was significantly lower in 
both Mild/Moderate (10.0 (range 0.0-39.0), p<0.05) and Severe COPD if 
compared with control healthy smokers (4.5 (range 0.0-65.0), p<0.05). In 
contrast, even in bronchial mucosa was observed an intensive 
immunopositivity for collagen type I (Figure 11, A), both collagen type I 
and pro-collagen type I expression did not show no significant variations 
when control patients were compared with diseased patients, as was 
observed for TGF-β1 and all Smads assessed (Table 6).  
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 Healthy Non 
smokers 
Healthy  
smokers 
Mild/Moderate 
COPD 
Severe COPD Kruskall 
Wallis  
p value 
Epithelium 
(score 0-3) 
Median 
(Range) 
Median 
(Range) 
Median  
(Range) 
Median 
(Range) 
 
PP2Cα 0.25 
(0.25-0.5) 
0.37 
(0.0-1.0) 
0.5 
(0.0-2.0) 
0.5 
(0.0-2.0) 
p=0.760 
CTGF 1.5 
(0.5-3) 
2.0 
(1.0-3.0) 
1.5 
(0.5-2.5) 
2.0 
(1.0-3.0) 
p=0.431 
TGF-β1 0.25 
(0.0-1.0) 
0.75 
(0.5-3.0)* 
1.5 
(0.0-2.5)* 
0.5 
(0.0-1.5) 
p=0.054 
TGF-β2 0.50 
(0.2-2.0) 
0.5 
(0.25-3.0) 
0.5 
(0.0-1.5) 
0.62 
(0.0-2.0) 
p=0.850 
TGF-β3 0.0 
(0.0-0.0) 
0.0 
(0.0-0.0) 
0.0 
(0.0-0.0) 
0.0 
(0.0-0.0) 
p=n.v. 
TβRI 0.0 
(0.0-0.0) 
0.0 
(0.0-0.0) 
0.0 
(0.0-1.0) 
0.0 
(0.0-0.0) 
p=0.334 
TβRII 0.5 
(0.2-2.0) 
0.5 
(0.0-3.0) 
0.5 
(0.0-2.0) 
1.0 
(0.0-2.0) 
p=0.405 
Smad 2 1.0 
(0.0-2.5) 
0.5 
(0.0-3.0) 
0.0 
(0.0-2.0) 
1.0 
(0.0-2.5) 
p=0.249 
Smad 3 1.0 
(0.0-2.0) 
0.0 
(0.0-3.0) 
0.5 
(0.0-1.5) 
1.0 
(0.0-2.5) 
p=0.468 
Smad 7 0.75 
(0.0-2.0) 
0.5 
(0.0-2.5) 
0.35 
(0.0-2.5) 
0.5 
(0.0-2.0) 
p=0.797 
p-Smad 2 0.5 
(0.0-1.0) 
0.25 
(0.0-0.5) 
0.0 
(0.0-0.5) 
0.0 
(0.0-1.5) 
p=0.514 
p-Smad 3 0.0 
(0.0-0.25) 
0.0 
(0.0-0.5) 
0.0 
(0.0-0.5) 
0.0 
(0.0-0.5) 
p=0.834 
Collagen I 0.25 
(0.0-0.5) 
0.5 
(0.0-1.0) 
0.0 
(0.0-1.0) 
0.5 
(0.0-0.5) 
p=0.749 
Pro collagen 
type I 
2.75 
(1.5-3.0) 
2.5 
(0.5-3.0) 
2.25 
(0.0-3.0) 
3.0 
(2.0-3.0) 
p=0.573 
 
Table 5: Statistical results for IHC in bronchial epithelium of COPD 
patients. * p<0.05 compared to control non smokers. 
 
 
 
Figure 11: Photomicrographs of bronchial biopsies. (A) The bronchial 
submucosa of Severe COPD immunostained for collagen type I+ cells; (B) 
The bronchial epithelium of a Severe COPD intensely immunostained for 
pro-collagen type I+ cells. Both immunostainings showed no significant 
variations when controls subjects were compared with diseased patients. 
Bar = 20µm. 
 
A B 20µm 20µm 
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 Healthy Non 
smokers 
Healthy  
smokers 
Mild/Moderate 
COPD 
Severe COPD Kruskall 
Wallis 
p value 
Submucosa 
(cells/mm2) 
Median 
(Range) 
Median 
(Range) 
Median  
(Range) 
Median 
(Range) 
 
PP2Cα 56.0 
(0.0-137.0) 
48.0 
(24.0-250.0) 
51.0 
(11.0-247.0) 
45.0 
(0.0-303.0) 
P=0.324 
CTGF 219.0 
(64.0-355.0) 
222.5(64.0-
387.0) 
178.5 
(17.0-355.0) 
224.0 
(39.0-484.0) 
p=0.693 
TGF-β1 53.0 
(5.0-236.0) 
33.5 
(0.0-333.0) 
48.0 
(0.0-195.0) 
30.0 
(0.0-230.0) 
p=0.705 
TGF-β2 40.0 
(8.0-507.0) 
103.0(24.0-
409.0) 
42.5 
(0.0-320.0)* 
57.5 
(0.0-560.0) 
p=0.074 
TGF-β3 0.0 
(0.0-13.0) 
16.0 
(6.0-58.0)* 
10.0 
(0.0-39.0)* 
4.5 
(0.0-65.0)* 
p=0.007 
TβRI 5.0 
(0.0-52.0) 
6.0 
(0.0-75.0) 
18.0 
(0.0-97.0) 
5.0 
(0.0-73.0) 
p=0.071 
TβRII 74.0 
(0.0-225.0) 
48.0 
(0.0-216.0) 
72.5 
(8.0-505.0) 
45.0 
(0.0-376.0) 
p=0.528 
Smad 2 181.5 
(0.0-750.0) 
166.5 
(50.0-514.0) 
51.0 
(0.0-960.0) 
91.5 
(4.0-627.0) 
p=0.530 
Smad 3 77.0 
(0.0-690.0) 
20.0 
(0.0-754.0) 
111.0 
(0.0-909.0) 
120.0 
(0.0-353,0) 
p=0.335 
Smad 7 67.0 
(11.0-300.0) 
48.5 
(0.0-584.0) 
96.0 
(0.0-520.0) 
56.5 
(0.0-620.0) 
p=0.949 
p-Smad 2 17.0 
(0.0-85.0) 
37.5 
(0.0-138.0) 
19.0 
(0.0-137.0) 
25.5 
(0.0-92.0) 
p=0.714 
p-Smad 3 67.0 
(38.0-107.0) 
65.0 
(45.0-161.0) 
113.0 
(52.0-215.0) 
78.0 
(14.0-237.0) 
p=0.113 
Collagen I 
Score (0-3) 
3.0 
(0.5-3.0) 
3.0 
(3.0-3.0) 
3.0 
(0.5-3.0) 
3.0 
(2.5-3.0) 
p=0.636 
Pro collagen I 
Score (0-3) 
2.75 
(1.5-3.0) 
2.0 
(1.0-3.0) 
2.5 
(1.0-3.0) 
1.87 
(1.0-3.0) 
p=0.594 
CTGF 
Score (0-3) 
1.5 
(0.5-2.0) 
2.0 
(1.0-3.0) 
1.5 
(0.5-2.0) 
1.5 
(0.75-2.5) 
p=0.289 
 
Table 6: Statistical results for IHC in bronchial submucosa of COPD 
patients. * p<0.05 compared to control non smokers. 
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Effects of CCL5 on TGF-β1-induced collagen type I mRNA  
In order to explain the pathological differences between fibrotic-like 
pulmonary disease, such as asthma and fibrosis, and COPD, we analyzed 
the effects of CCL5 on the TGF-β1-induced collagen type I production. 
Recently, we demonstrated an increased expression of CCL5 mRNA and a 
significantly increased number of CCL5+ cells in the bronchial mucosa of 
severe COPD compared to controls (Di Stefano et al, 2009). Then, in order 
to explain the immunohistochemical results observed previously, we 
performed a new in vitro study in which cells were treated simultaneously 
with TGF-β1 and CCL5. Analysis of RNA revealed that collagen type I 
transcription decreased in a dose-dependent manner when cells were treated 
contemporary with TGF-β1 and with increasing doses of CCL5 and 
specifically, we observed a significant reduction of the TGF-β1-induced 
collagen type I mRNA after treatment with 10ng/ml of both TGF-β1 and 
RANTES if compared with control (p=0.0232) and if compared with cells 
treated with 10ng/ml of TGF-β1 (p=0.0015) for 24h (Figure 12). When 
16HBE were treated for different time of exposure we observed that with 
respect to control, CCL5 was able to induce a pro-fibrotic effect on cells, 
with a significant stimulation of collagen type I transcription at 3h 
(p=0.0017) and at 24h (p=0.0433). However, treatments with both TGF-β1 
and CCL5 caused a reduction of TGF-β1-induced collagen type I mRNA 
(p=0.0015) at 24h suggesting a down-regulatory role of CCL5 in human 
bronchial epithelial cells (Figure 13).  
These findings indicate that TGF-β1 is able to induce the fibrotic response 
of 16HBE stimulating collagen type I transcription and secretion, 
suggesting the possible involvement of bronchial epithelial cells in 
maintenance of pro-fibrotic events in different lung diseases. Furthermore, 
these data confirm the role performed by TGF-β1 in human tissue and the 
importance of this cytokine in regulating ECM production and remodelling. 
Interestingly, when we treated cells with CCL5 there was a dose-dependent 
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reduction of TGF-β1-induced collagen transcription and secretion with a 
significant reduction, particularly at a dosage of 10ng/ml. The observed 
effects of CCL5 treatment in vitro could confirm data obtained in vivo in 
bronchial biopsies and can explain the lack of extended pro-fibrotic events 
and the increased levels of TGF-β-2-3+ cells observed in Severe COPD. 
 
Effects of CCL5 on TGF-β1-induced Smads mRNA and protein 
expression 
16HBE treated with 10ng/ml of CCL5 showed a reduction of TGF-β1-
induced Smads transcription. Specifically we observed a significant 
reduction of TGF-β1-induced Smad3 and Smad4 mRNA after 24h of 
exposure (p=0.0293 and p=0.0052, respectively) (Figure 14, A-B); in 
contrast Smad7 transcription appeared to be stimulated by CCL5 even if we 
did not observe any significant value for treatments with simultaneous 
administration of TGF-β and CCL5 at 24h (Figure 14, C). Additionally, 
sub-fractionated western blotting analysis revealed that treatments with 
TGF-β1 and CCL5 caused a significant reduction of active p-smad3 into 
the nucleus (p=0.0381), suggesting an involvement of this chemokine in its 
post-translational regulation (Figure 15). These data found confirmation 
after immunolocalization of p-Smad3: with respect to control, we observed 
that TGF-β1 is able to enhance the number of p-smad3+ cells with a 
consistent nuclear localization (Figure 16, B-E). In contrast treatment with 
CCL5 is able to reduce the TGF-β1-induced number of positive cells in 
both cytoplasm and nucleus (Figure 16, D-F). However, precise mechanish 
by which CCL5 interferes on induced-Smad3 phosphorylation is not clear 
and lack any explanation. We need to investigate further the role of CCL5 
on nuclear translocation. 
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Figure 12: CLL5 dose-dependent reduction of TGF-β-induced collagen 
type I transcription.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Collagen type I transcription after treatments with TGF-β1, 
CCL5 and both TGF-β1 and CCL5.  
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Figure 14: Effects of CCL5 on TGF-β1-induced Smads transcription 
A) Smad3 mRNA; B) Smad4 mRNA; C) Smad7 mRNA. 
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Figure 15: Effects of CCL5 on p-Smad3 into nucleus. A-B) CCL5 
reduced TGF-β1-induced nuclear p-Smad3 expression; C) Western blotting 
results for nuclear p-smad3 after 24h of treatments. 
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Figure 16: Immunocytochemistry demonstration of p-smad3 positive 
16HBE cells after treatments. A) Untreated control; B) TGF-β1 10ng/ml; 
C) CCL5 10ng/ml; D) TGF-β1+CCL5 10ng/ml. Magnification 40x. E) 
TGF-β1 10ng/ml; F) TGF-β1+CCL5 10ng/ml. Magnification 63x. 
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ERK is a possible regulatory transductor of CCL5 signaling 
To explain the molecular pathway by which CCL5 was able to down- 
regulate TGF-β1-induced effects on 16HBE we analyzed the molecular 
signaling pathway of this chemokine. Data in literature revealed that 
RANTES exhibits its effect acting through three CC chemokine receptors, 
CCR1, CCR2 and CCR3 (New et al, 2003). As visible in Figure 17 these 
are G-Protein-coupled receptors (GPCRs) which activate an intercellular 
signaling pathway in which are involved several MAPKs. 
As discussed previously the biological effects of TGF-β1 are mediated not 
only by Smads signaling but also by MAPKs. According to this, we 
evaluated the effects of JNK, p38 and ERK transduction pathway inhibition 
to assess a possible correlation with the observed CCL5-mediated effects. 
Interestingly, we observed that JNK and p-38 appeared not to be involved 
in collagen type I transcription (data not shown); in contrast treatments with 
ERK inhibitor caused a significant reduction of TGF-β1-induced collagen 
type I mRNA level (p=0.0020) compared with cells not treated with 
inhibitor, and as visible in Figure 18, a further reduction of the effects 
mediated by CCL5 (p=0.0020). These results suggest a possible regulatory 
role for ERK and could explain the molecular mechanism involved in this 
type of inflammation and collagen production. 
 
Effects of TGF-β1 and CCL5 on cellular viability  
In order to explain results obtained, we analyzed the effects of treatments 
on cellular viability and on morphological characters. Exposure of human 
bronchial epithelial 16HBE cells to TGF-β1, CCL5 and both together TGF-
β1 and CCL5 was accomplished after a starvation period of 24h and the 
viability assay was performed using MTT test. As visible in Figure 19 there 
were no statistical changes on cellular viability after all treatments if 
compared with controls, and through a phenotypical analysis of cultured 
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cells we observed that TGF-β and CCL5 did not alter the typical features of 
bronchial epithelial cells. MTT test was performed also for cells treated 
with ERK inhibitor just to exclude any reduction of viability and have 
another confirmation of results obtained. Similarly the treatment with the 
specific ERK inhibitor had not effect on cellular viability and cells 
displayed no morphological changes. 
 
 
 
 
 
 
 
 
 
 
Figure 17: Intracellular signaling pathway activated by CC chemokine 
receptors. Dashes lines indicate that the role of intermediated proteins has 
not yet been elucidated (New et al, 2003). 
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Figure 18: Effects of ERK inhibition on collagen type I transcription. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: MTT assay to value cellular viability of 16HBE after 
treatments. 
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CONCLUSIONS 
It has been reported that destruction of TGF-β1 signaling system is 
involved in several pulmonary diseases, such as pulmonary fibrosis and 
COPD. Actually, TGF-β1 is involved in regulation of turnover of 
connective tissue and ECM components (Sporn et al, 1992; Blobe et al, 
2000; Barànek et al, 2002; Bonniaud et al, 2005), and elevated levels of this 
growth factor have been observed in both bronchial epithelium (De Boer et 
al, 2000) and alveolar epithelium (De Boer et al, 1998) of COPD patients, 
leaving us hypothesize a relationship with the airway remodelling 
characterizing this disease. This study demonstrated that in bronchial 
biopsies of COPD patients there was a significant enhance of TGF-β1 
immunostained cells in bronchial epithelium of Mild/Moderate COPD 
compared with control healthy smokers; however, we did not observe any 
variation for TGF-β1 in bronchial submucosa and, similarly, any change for 
collagen and procollagen type I immunostained cells as in epithelium as in 
submucosa. TGF-β1 signaling is mediated through Smads protein 
(Massuguè, 2005, 2006; Moustakas et al, 2009). Several investigators 
showed that Smad3 is principally related to the fibrotic phenotype induced 
by TGF-β1 and is involved in the pathogenic mechanism mediating tissue 
destruction and fibrogenesis (Bonniaud et al, 2004; Zeisberg et al, 2007). 
To value the role of Smads in mediating TGF-β1 signaling we analyzed 
mRNA and protein expressions in human bronchial epithelial 16HBE cells 
after treatments with different doses of TGF-β1 and for different time of 
exposure. Our study on mRNA revealed that TGF-β1 was able to stimulate 
significantly collagen type I transcription in a time and dose-dependent 
manner and confirmed that it is able to stimulate Smad3, Smad4 and Smad7 
transcription causing a significative increase of mRNA level. Furthermore, 
we demonstrated that TGF-β1 caused a significative increase of nuclear 
phospho-Smad3, let us supposing a direct involvement in TGF-β1-induced 
collagen type I transcription. The IHC analysis on bronchial biopsies 
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revealed also that, in contrast with results obtained for TGF-β1 expression, 
there were no significant changes for all Smads analyzed in all four groups 
of subjects and COPD patients. These results seem to be in contrast with 
results obtained in vitro and suggest us a possible inhibitory mechanism of 
TGF-β1 stimulus in vivo. Recently, we observed that in the bronchial 
mucosa of Severe COPD the number of CCL5+ immunostained cells was 
significantly higher than controls (Di Stefano et al, 2009). These results 
suggested a possible mechanism in which CCL5 is involved in modulating 
TGF-β1-induced effects. We demonstrated that CCL5 is able to reduce in a 
dose-dependent manner TGF-β1-induced effects on collagen type I and 
Smads transcription and significantly reduce nuclear phospho-Smad3 
accumulation in 16HBE cells. Our results let us hypothesized that CCL5 
down-regulates TGF-β1-induced effects and that the inhibitory mechanism 
is, at least in part, mediated by ERK transduction pathway, as confirmed 
through the use of ERK inhibitor which was able to significantly reduce 
CCL5-mediated anti-fibrotic effects in bronchial epithelial 16HBE. 
To our knowledge this is the first description of an inhibitory mechanism 
for TGF-β1-induced fibrotic effects. Furthermore, on the basis of our 
results, we hypothesised that our in vitro model could explain, a least in 
part, the pathological differences existing in vivo between asthma, 
characterized by increased bronchial fibrosis, and COPD characterized by a 
low level of collagen deposition in the bronchi. Further examination of this 
mechanism could lead to a better understanding of anti-fibrotic function 
of CCL5 and may represent a point of effective therapeutic intervention 
for fibrotic diseases. However the role performed by CCL5 and the 
molecular mechanism activated by this chemokine needs more study. 
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